News
Mutual Funds and ETFs Scorecard: May 27 Edition
Iuri Struta
|
After weeks of poor performance, markets have reversed losses and small-caps have been...
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
Symbol | Mutual Fund | Stake |
---|---|---|
{% mutualfund VTSMX %} | Vanguard Total Stock Mkt Idx | 1.37% |
{% mutualfund FCNTX %} | Fidelity® Contrafund® | 1.34% |
{% mutualfund VFINX%} | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
News
Iuri Struta
|
After weeks of poor performance, markets have reversed losses and small-caps have been...
Justin Kuepper
|
Let's take a look at how these trends have played out in actively-managed...
Justin Kuepper
|
Let's take a closer look at whether transparency really matters for portfolio managers...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
Symbol | Mutual Fund | Stake |
---|---|---|
{% mutualfund VTSMX %} | Vanguard Total Stock Mkt Idx | 1.37% |
{% mutualfund FCNTX %} | Fidelity® Contrafund® | 1.34% |
{% mutualfund VFINX%} | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
News
Iuri Struta
|
After weeks of poor performance, markets have reversed losses and small-caps have been...
Justin Kuepper
|
Let's take a look at how these trends have played out in actively-managed...
Justin Kuepper
|
Let's take a closer look at whether transparency really matters for portfolio managers...
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...